Search

Type

Audience

Category

Issue

Last updated

Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.

Displaying 1 - 5 of 5 items.

" " Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancer
The Canadian labelling for all Janus Kinase (JAK) inhibitors is being updated to include the risks of serious heart-related problems, fatal blood clots and cancer. This is being done as a precautionary measure. To date, Canadian labelling for the drugs…
AlertPublic advisory | 2022-11-01
" " Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
Pharmascience Inc. is recalling one lot of pms-Hydromorphone, 2 mg tablets, (lot 639268) as the bottles may contain hydromorphone tablets of a different strength (8 mg), meaning they contain higher amounts of hydromorphone. Products from the affected lot…
AlertPublic advisory | 2022-08-20
" " Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured (macro-textured) implants
Health Canada has updated its 2019 and 2017 safety reviews on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious cancer of the immune system that can develop next to a breast implant. This review found that there…
AlertPublic advisory | 2022-04-06
" " Lichtenberg generators pose life-threatening danger to users
Health Canada is aware of six reports of fatal injuries in Canada since 2017 resulting from the use of wood-burning devices know as Lichtenberg generators. This information was reported from provincial and territorial electrical safety authorities.…
AlertPublic advisory | 2022-01-19
" " Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer
UPDATE - January 12, 2022: Safety Review found a link between the use of Xeljanz/Xeljanz XR (tofacitinib) and the risks of serious heart-related problems and cancer Health Canada completed a safety review that confirmed a link between the use of…
AlertPublic advisory | 2022-01-12
Report a problem or mistake on this page
What was wrong?

If you want to receive a follow-up reply, please include your name and e-mail address.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.